Issues impacting therapeutic outcomes in pediatric patients: an overview

Area of Science:

• Pediatric pharmacology
• Drug formulation science
• Healthcare outcomes research

Background:

• Suboptimal therapeutic outcomes in children are often linked to a lack of child-specific dosage forms.
• Legislation such as the Best Pharmaceutical for Children Act (BPCA) and Pediatric Research Equity Act (PREA) aims to encourage the development of pediatric formulations.
• Past initiatives by organizations like the World Health Organization (WHO) have improved pediatric treatments for diseases like HIV and malaria.

Purpose of the Study:

• To review the advancements and persistent challenges in developing child-friendly dosage forms.
• To highlight the impact of regulatory and organizational initiatives on pediatric drug development.
• To identify factors beyond formulation that influence pediatric therapeutic outcomes.

Main Methods:

• Review of existing literature and regulatory frameworks concerning pediatric drug formulation.
• Analysis of initiatives by governmental and non-governmental organizations.
• Discussion of current trends in pediatric dosage form development, including oro-dispersible platforms.

Main Results:

• Significant legislative and organizational efforts have been made to incentivize the development of pediatric-specific medications.
• Innovations in dosage forms, such as thin films and mini-tablets, are emerging.
• Despite formulation advancements, challenges related to parental understanding of instructions and pediatric clinical trial complexities remain.

Conclusions:

• While progress has been made in creating child-friendly dosage forms, achieving optimal pediatric therapeutic outcomes requires addressing broader issues.
• A multidisciplinary approach involving pharmaceutical companies, researchers, parents, and healthcare providers is essential.
• Continued focus on improving medication adherence and simplifying clinical research is necessary for better pediatric care.